RA'ANANA, Israel, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that a national ministry of health in Africa (the “Ministry of Health”) has placed a $27 million binding purchase order for Inspira’s FDA-cleared ART100 systems. The purchase order, secured through Inspira’s exclusive distribution partner, dedicated solely to the commercialization of Inspira’s products, initiates an immediate nationwide deployment program.
Related Questions
How will the $27 million binding purchase order affect Inspira’s revenue and earnings forecasts for 2025?
When is the cash from the Ministry of Health expected to be received and reflected in the company’s balance sheet?
What does this contract indicate about Inspira’s competitive positioning and market share relative to other life‑support technology providers?